Lakefront Biotherapeutics (LKFT) Non-Current Assets (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has 13 years of Non-Current Assets data on file, last reported at $364.9 million in Q1 2026.

• Non-Current Assets for Q1 2026 came in at $364.9 million, down 36.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $364.9 million (down 36.88% YoY), and the FY2025 annual result was $380.7 million, changed 0.42% from the prior year.
• Non-Current Assets eased to $364.9 million in Q1 2026 per LKFT's latest filing, from $380.7 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $673.0 million in Q3 2024 and troughed at $3.1 million in Q4 2022.
• A 5-year average of $449.6 million and a median of $409.0 million in 2025 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2023 and 2025: Non-Current Assets soared 11143.28% in 2023, then slumped 39.22% in 2025.
• A 5-year view of Non-Current Assets shows it stood at $3.1 million in 2022, then soared by 11143.28% to $348.4 million in 2023, then advanced by 9.74% to $382.3 million in 2024, then dropped by 0.42% to $380.7 million in 2025, then dropped by 4.15% to $364.9 million in 2026.
• Business Quant data shows LKFT's Non-Current Assets at $364.9 million in Q1 2026, $380.7 million in Q4 2025, and $409.0 million in Q3 2025.